

ADHD SIDE EFFECTS AND INTERVENTION CHART

COMMON SIDE EFFECTS	POTENTIAL INTERVENTIONS
Significant weight loss or failure to gain weight and/or decreased appetite	<ul style="list-style-type: none"> • Reduce, change, or discontinue medication. • Administer medication with meals (big breakfast before meds). • Improve caloric intake with nutritious, high-caloric drinks/snacks. • Planned bedtime snack. • “Medication holiday” (discontinue medication on weekends/vacations). • Cyproheptadine has been shown to stimulate weight gain.
Sleep disruption—difficultly falling or staying asleep	<ul style="list-style-type: none"> • Promotion of bedtime ritual/routine and good sleep hygiene. • Reduce stimulant dosage, especially afternoon dosages of short-acting stimulants. • Assess for rebound effect (see below). • Low doses of sleep aid medications (such as melatonin) if alteration in dose or administration schedule is ineffective. • Assess need for consult to determine presence of sleep disorder.
Rebound effect (increase in hyperactivity/impulsivity in the evening when the stimulant is no longer effective)	<ul style="list-style-type: none"> • Switch to or increase dose of long-acting medication or add a short-acting medication during rebound period. • Overlap stimulant preparations to cover the “rebound” period. • Add a non-stimulant to regimen to smooth out effects. • Psychotherapeutic intervention to gain assistance managing these behaviors when the medication wears off.
Headache	<ul style="list-style-type: none"> • Dose adjustment or change in medication. Consider use of another stimulant or a non-stimulant medication. • Encourage adequate fluid intake/hydration. • If using Strattera, splitting the dosage is often effective.
Stomachache	<ul style="list-style-type: none"> • Administer dose during or after meals. • Discourage taking medication on an empty stomach. • Discuss possibility of providing the child with smaller, more frequent meals to see if that reduces stomachaches/nausea. • Dose adjustment or change in medication.
Dizziness/Lightheadedness	<ul style="list-style-type: none"> • Check pulse and blood pressure. • Encourage adequate fluid intake/hydration. • If symptoms associated with peak stimulant effect, consider use of long-acting preparation.
New emotional and/or behavioral symptoms such as anxiety, affective blunting, depressed mood, or irritability.	<ul style="list-style-type: none"> • Determine if irritability occurs at peak drug effect or if associated with rebound. If related to peak effect, consider reducing stimulant dose, switching to long-acting stimulant, or switching to a different stimulant or non-stimulant treatment. If related to rebound, consider low sensory environment to offset and see suggestions above.
UNCOMMON, BUT POTENTIALLY SERIOUS SIDE EFFECTS	POTENTIAL INTERVENTIONS
Motor tics/Vocal tics	<ul style="list-style-type: none"> • Determine the relationship between tics and stimulant use, including time of onset and dose-response relationships. • If tics resolve after first 7 to 10 days, it may be reasonable to review informed consent with patient and family and continue medication. • Other options include switching to a different stimulant or non-stimulant medication. • Use of an alternative stimulant or a non-stimulant medication. • Combined therapy of stimulant with an alpha agonist.

ADHD SIDE EFFECTS AND INTERVENTION CHART

UNCOMMON, BUT POTENTIALLY SERIOUS SIDE EFFECTS	POTENTIAL INTERVENTIONS
<p>Cardiac Events</p> <ul style="list-style-type: none"> • Increase in heart rate and/or blood pressure • Palpitations/Rapid or irregular heartbeat • Cardiac arrhythmias are rare, but sudden death has been reported in association with stimulants, most notably mixed amphetamine salts. 	<ul style="list-style-type: none"> • Modify, change, or discontinue medication. • Currently, there is no evidence for the need for routine cardiac evaluation such as electrocardiography or echocardiography; however, children with a history of pre-existing heart disease or symptoms suggestive of syncope and cardiovascular disease should be managed carefully. • The American Academy of Pediatrics recommends assessment of all children before initiating ADHD medications with a targeted cardiac history, including cardiac disease, palpitations, syncope, seizures, family history of sudden death, hypertrophic cardiomyopathy, and long QT syndrome. Positive findings would require additional evaluation and potential consultation with a pediatric cardiologist prior to stimulant medications.
<p>Skin Rash/Itching/Hives</p>	<ul style="list-style-type: none"> • Modify, change, or discontinue medication. • Most likely if using Daytrana patch. Vary application sites and be sure to remove at 9 hours.
<p>Manic/Hypomanic symptoms (excessive energy, elevated mood, grandiose thoughts, euphoria or irritability, and a decreased need for sleep)</p>	<ul style="list-style-type: none"> • Modify, change, or discontinue medication. • Assess family history of bipolar disorder. • If comorbid ADHD and bipolar disorder, prioritize mood stabilization before ADHD treatment.
<p>Psychosis (auditory, visual, and tactile hallucinations [i.e., hearing, seeing, or feeling things that are not there] and/or delusions [e.g., paranoia])</p>	<ul style="list-style-type: none"> • Modify, change, or discontinue medication. • Assess for comorbid psychotic disorder. Stimulants should not be prescribed to psychotic patients.
<p>Jaundice (yellow skin or eyes, dark urine, and/or pale stools)</p>	<ul style="list-style-type: none"> • Can indicate liver inflammation (hepatitis) caused by medication. This rare reaction is likely a concern only with Strattera. • Change or discontinue medication.
<p>Seizure/Convulsion</p>	<ul style="list-style-type: none"> • Consult with a specialist.
<p>Rare side effects include extreme mood lability, increased aggression, emotional distress, or suicidal thoughts or behaviors</p>	<ul style="list-style-type: none"> • Assess need for referral or emergency evaluation. • Change or discontinue medication.

SOURCES: 1. ADHD Medication Telephone Care Management Manual by John V. Campo, M.D., Jack Stevens, Ph.D., Kelly Kelleher, M.D., and L. Eugene Arnold, M.D.
2. Pediatric Psychiatry Network. [Attention Deficit Hyperactivity Disorder and Primary Care](#).

NOTES: This resource is for reference purposes only and should not be used to replace medical information from prescribing health care professionals or pharmacies.